Allergan, Inc.

John R Cappiello

Todd M Heidelbaugh

Phong X Nguyen

Michael E Garst

Ken Chow

Daniel W Gil

Larry Allen Wheeler

Dario G Gomez

John E Donello

Janet A Takeuchi

Karen M Kedzie

The present invention relates to novel 2-oxo-2H-chromene-3-carboxamide derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.

Coumarin compounds as receptor modulators with therapeutic utility

The present invention relates to novel amine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.

Compounds as receptor modulators with therapeutic utility

Compounds of Formula 1 where the variables have the meaning defined in the specification are used to activate alphaadrenergic receptors. The compounds of Formula 1 are incorporated in pharmaceutical compositions and are used as medicaments in mammals, including humans, for treatment of diseases and or alleviations of conditions which are responsive to treatment by agonists of alphaadrenergic receptors.

[object Object]

Substituted 2-aminotetralin derivatives as selective alpha 2B agonists can be incorporated in a pharmaceutical composition and can be used in methods of treating an alpha 2B receptor mediated diseases or conditions. The compounds are represented by Formula 1: 

Substituted 2-aminotetralin derivatives as selective alpha 2B agonist

Unsubstituted and substituted 4-benzyl-1,3-dihydro-imidazole-2-thiones acting as specific or selective alpha2 adrenergic agonists and methods for using the same

Growing community of inventors

Irvine, CA, United States of America

John R Cappiello